A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
NCT00627627 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2010-02-03
Summary
To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.
Conditions
Interventions
- DRUG
-
IPI-504
dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
Sponsors & Collaborators
-
MedImmune LLC
lead INDUSTRY
Principal Investigators
-
David E. Weng, M.D., PhD · MedImmune LLC
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2010-02-28
Countries
- United States
Study Locations
More Related Trials
-
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
NCT04296370 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients
NCT07197697 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
NCT00600275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
NCT03980054 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190 ·Status: RECRUITING ·Phase: PHASE2
-
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NCT07182721 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
NCT04927481 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239 ·Status: RECRUITING ·Phase: PHASE3
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
NCT05905341 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
NCT05504213 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533 ·Status: COMPLETED ·Phase: PHASE2
-
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
NCT03084237 ·Status: COMPLETED ·Phase: PHASE3
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT02453620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
NCT05806671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
NCT01476111 ·Status: TERMINATED
-
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029 ·Status: RECRUITING ·Phase: PHASE1
-
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
NCT04251169 ·Status: TERMINATED ·Phase: PHASE2